Terms: = Endocrine gland cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S
209 results:
1. Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian cancer, Cologne.
Kast K; Rhiem K; Larsen M; Wappenschmidt B; Schmutzler R
Cancer Med; 2024 Feb; 13(3):e6920. PubMed ID: 38230850
[TBL] [Abstract] [Full Text] [Related]
2. Exploration and validation of key genes associated with early lymph node metastasis in thyroid carcinoma using weighted gene co-expression network analysis and machine learning.
Liu Y; Yin Z; Wang Y; Chen H
Front Endocrinol (Lausanne); 2023; 14():1247709. PubMed ID: 38144565
[TBL] [Abstract] [Full Text] [Related]
3. Stromal-derived NRG1 enables oncogenic KRAS bypass in pancreas cancer.
Han J; Xu J; Liu Y; Liang S; LaBella KA; Chakravarti D; Spring DJ; Xia Y; DePinho RA
Genes Dev; 2023 Sep; 37(17-18):818-828. PubMed ID: 37775182
[TBL] [Abstract] [Full Text] [Related]
4. Vemurafenib activates the sonic hedgehog pathway and promotes thyroid cancer stem cell self-renewal.
Lu Y; Zhao Y; Liu P; Xu X
Endocr Relat Cancer; 2023 Nov; 30(11):. PubMed ID: 37643458
[TBL] [Abstract] [Full Text] [Related]
5. Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating her3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways.
Dang H; Sui M; He Q; Xie J; Liu Y; Hou P; Ji M
Int J Biol Macromol; 2023 Sep; 248():125867. PubMed ID: 37473892
[TBL] [Abstract] [Full Text] [Related]
6. her3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma.
Desai O; Wang R
Oncotarget; 2023 May; 14():439-443. PubMed ID: 37163206
[TBL] [Abstract] [Full Text] [Related]
7. MicroRNA-592 Inhibits the Growth of Ovarian cancer Cells by Targeting erbb3.
Jin Q; Zhang N; Zhan Y; Xu X; Han C; Zhao H; Hu X; Tang H; Wu Y
Technol Cancer Res Treat; 2023; 22():15330338231157156. PubMed ID: 36916303
[No Abstract] [Full Text] [Related]
8. Disulfiram/Cu Kills and Sensitizes
Xie J; Liu J; Zhao M; Li X; Wang Y; Zhao Y; Cao H; Ji M; Chen M; Hou P
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834830
[No Abstract] [Full Text] [Related]
9. Feasibility of Co-Targeting her3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic cancer Xenograft Model.
Xu T; Schulga A; Konovalova E; Rinne SS; Zhang H; Vorontsova O; Orlova A; Deyev SM; Tolmachev V; Vorobyeva A
Int J Mol Sci; 2023 Feb; 24(3):. PubMed ID: 36769161
[TBL] [Abstract] [Full Text] [Related]
10. Influence of Hashimoto thyroiditis on diagnosis and treatment of thyroid nodules.
Mao L; Zheng C; Ou S; He Y; Liao C; Deng G
Front Endocrinol (Lausanne); 2022; 13():1067390. PubMed ID: 36619577
[TBL] [Abstract] [Full Text] [Related]
11. Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors.
Garcia-Rendueles MER; Krishnamoorthy G; Saqcena M; Acuña-Ruiz A; Revilla G; de Stanchina E; Knauf JA; Lester R; Xu B; Ghossein RA; Fagin JA
Mol Cancer; 2022 Dec; 21(1):213. PubMed ID: 36476495
[TBL] [Abstract] [Full Text] [Related]
12. Radioactive Iodine-Refractory Pulmonary Metastases of Papillary Thyroid cancer in Children, Adolescents, and Young Adults.
Tian T; Huang S; Dai H; Qi M; Liu B; Huang R
J Clin Endocrinol Metab; 2023 Jan; 108(2):306-314. PubMed ID: 36226635
[TBL] [Abstract] [Full Text] [Related]
13. PIK3R3, a regulatory subunit of PI3K, modulates ovarian cancer stem cells and ovarian cancer development and progression by integrative analysis.
Sohn EJ
BMC Cancer; 2022 Jun; 22(1):708. PubMed ID: 35761259
[TBL] [Abstract] [Full Text] [Related]
14. ROS and miRNA Dysregulation in Ovarian cancer Development, Angiogenesis and Therapeutic Resistance.
Stieg DC; Wang Y; Liu LZ; Jiang BH
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743145
[TBL] [Abstract] [Full Text] [Related]
15. Search for New Target Genes of MicroRNA for Differential Diagnosis of Benign and Malignant Neoplasms of the Thyroid gland by In Silico Methods.
Kononchuk VV; Kopeikina EV; Kalinina TS; Saik OV; Alekseenok EY; Kolyagina MK; Matashova VA; Shevchenko SP; Gulyaeva LF; Kushlinskii NE
Bull Exp Biol Med; 2022 Jun; 173(2):246-251. PubMed ID: 35737153
[TBL] [Abstract] [Full Text] [Related]
16. In Vitro Tumor Cell-Binding Assay to Select High-Binding Antibody and Predict Therapy Response for Personalized
Hihara F; Matsumoto H; Yoshimoto M; Masuko T; Endo Y; Igarashi C; Tachibana T; Shinada M; Zhang MR; Kurosawa G; Sugyo A; Tsuji AB; Higashi T; Kurihara H; Ueno M; Yoshii Y
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628616
[TBL] [Abstract] [Full Text] [Related]
17. The significance of ErbB2/3 in the conversion of induced pluripotent stem cells into cancer stem cells.
Hassan G; Zahra MH; Seno A; Seno M
Sci Rep; 2022 Feb; 12(1):2711. PubMed ID: 35177646
[TBL] [Abstract] [Full Text] [Related]
18. Identification of a DNA repair 9-gene signature for the overall survival prediction of pancreatic cancer.
Huang J; Mao Q; Sun X
Ann Diagn Pathol; 2022 Apr; 57():151883. PubMed ID: 35123152
[TBL] [Abstract] [Full Text] [Related]
19. Enhancing Radioiodine Incorporation in
Tchekmedyian V; Dunn L; Sherman E; Baxi SS; Grewal RK; Larson SM; Pentlow KS; Haque S; Tuttle RM; Sabra MM; Fish S; Boucai L; Walters J; Ghossein RA; Seshan VE; Knauf JA; Pfister DG; Fagin JA; Ho AL
Thyroid; 2022 Mar; 32(3):273-282. PubMed ID: 35045748
[No Abstract] [Full Text] [Related]
20. The potential targeted drugs for fusion genes including NRG1 in pancreatic cancer.
Umemoto K; Sunakawa Y
Crit Rev Oncol Hematol; 2021 Oct; 166():103465. PubMed ID: 34454058
[TBL] [Abstract] [Full Text] [Related]
[Next]
